Gene testing firm Natera's Q4 revenue rises 39.8%

Natera

26/02/2026 21:40

Overview

Genetic testing firm's Q4 revenue rose 39.8% yr/yr, driven by product revenue growth

Company's Q4 gross margin improved to 66.9% from 62.9% yr/yr

Processed 54.7% more oncology tests in Q4 2025 compared to prior year

Outlook

Natera anticipates 2026 total revenue of $2.62 bln to $2.70 bln

Company expects 2026 gross margin to be approximately 63% to 65%

Natera projects positive net cash inflow for 2026

Result Drivers

PRODUCT REVENUE GROWTH - Driven by increased test volumes and higher average selling prices

ONCOLOGY TEST VOLUME - Processed 54.7% more oncology tests in Q4 2025, boosting revenue

GROSS MARGIN IMPROVEMENT - Higher revenues and cost reductions in test processing improved margins

Company press release: ID:nBw1BjTXLa

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Income from Operations
-$22.80 mln
Q4 Operating Expenses
$466.50 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 20 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the healthcare facilities & services peer group is "buy"

Wall Street's median 12-month price target for Natera Inc is $265.00, about 25.1% above its February 25 closing price of $211.83

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)